Background {#Sec1}
==========

Autism spectrum disorder (ASD) is a group of early onset and heterogeneous neurodevelopmental disorders affecting males (1/42) more often than females (1/189) \[[@CR1]\]. The prevalence of ASD has risen rapidly; from 0.5/1000 people in early epidemiological studies of 1960--1970 \[[@CR2], [@CR3]\] to 1/68 children of school age according to recent data from the Centre for Disease Control \[[@CR1]\].

ASD is characterised by atypical development of social behaviour, communication deficits and the presence of repetitive and stereotyped behaviours \[[@CR4]\]. It is highly clinically heterogeneous and accompanied by commonly occurring comorbidities that are not core to the disorder but frequently disabling. Communication deficit also persists in social communication disorder (SCD), and the new diagnosis of SCD (DSM-5) makes it possible to distinguish ASD from SCD individuals. The severity may vary across a range of parameters including ASD symptoms, IQ and comorbid behaviours \[[@CR4]\]. For example, 70% ASD patients will have at least 1 comorbid psychiatric disorder \[[@CR5]\], such as social anxiety, depression and bipolar disorder \[[@CR6]\]. In addition, ASD is frequently associated with epilepsy, gastrointestinal and immune disorders \[[@CR7]\].

ASD is a highly heritable complex polygenic condition. Estimated heritability based on family and twin studies are 50--80% \[[@CR8], [@CR9]\]. It is strongly linked to genetic factors involving the development and function of the nervous system \[[@CR10]\], mitochondrial function \[[@CR11]\], the immune system \[[@CR12]\] and epigenetic regulations \[[@CR13]\]. Genetic risk is attributed to rare copy number variants (CNV) and single nucleotide variants (SNV) acting on the background of common genetic variation (reviewed by \[[@CR14]\]). High throughput genome sequencing technologies have facilitated genomic discovery, and advanced bioinformatics methodologies have enabled investigation of protein-protein interactions \[[@CR15], [@CR16]\] and functionally related pathways \[[@CR17], [@CR18]\]. The pathway to gene discovery has required large-scale international collaborative efforts based on the assembly of large bio-collections that are now publicly available and the subject of this review. In parallel to bio-collections, large-scale patient registries have provided epidemiological data that illustrate the course and prognosis of ASD and are helping to identify environmental factors influencing the aetiology \[[@CR19]--[@CR22]\]. Despite the advances, significant gaps in our knowledge of the aetiology remain and effective treatments for core ASD symptoms are elusive. The genetic and clinical heterogeneity of ASD means that further advancement will require larger bio-collections coupled with rich clinical data, ideally longitudinally to obtain a clear picture of the disorder both on the molecular and physiological levels.

Autism bio-collections {#Sec2}
----------------------

A bio-collection is a large set of biologically characterised samples, such as blood or tissue collected from a group of individuals who typically have a specific medical condition. Bio-collections are useful as a dedicated resource to generate clinical and scientific data for the analysis of medical conditions on a large scale \[[@CR23]\], as well as to create functional disease models to explore the biology of clinical conditions. Large-scale bio-collections and associated comprehensive data that can aid the interrogation of the relationship between the genotype and phenotype effects at the individual and group levels can address the issue of heterogeneity. The purpose of this review is to provide a summary of the publicly available ASD bio-collections, to highlight the impact of these on ASD research and to identify new directions for ASD bio-collection for future research purposes.

Methods and search criteria {#Sec3}
===========================

A literature search was conducted amongst published studies from Jan 2001 to Nov 2016 on electronic databases of Web of Science, EBSCO, PubMed, Science Direct, MEDLINE, Wiley Online Library. The search terms included "biobank", "registry", "collection", "autism" and citation of bio-collections. A total of 263 studies from ASD bio-collections have been included in the tables and references of this review (Tables [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"}, [4](#Tab4){ref-type="table"}, [5](#Tab5){ref-type="table"} and [6](#Tab6){ref-type="table"}).

Inclusion criteria {#Sec4}
------------------

This review included (a) studies using original samples of human tissues in ASD bio-collections; (b) studies using bio-samples extracted from systematically collected bio-resources (i.e. DNA, RNA, protein) for investigating the risk or influence of ASD; (c) the population studies involving participants of autism, Asperger and pervasive developmental disorder not otherwise specified (PDD-NOS); (d) studies published in peer-reviewed journals and (e) in English.

Exclusion criteria {#Sec5}
------------------

Studies were excluded (**a**) if they did not mention the collection(s) in the research data, references, acknowledgements or supplementary materials; (**b**) if the bio-samples were not derived from a systematic sample collection; and (**d**) if studies only concerned animal models of ASD without using ASD bio-collections or data.

We focus largely on studies from five bio-collections, four providing DNA, cell lines and metabolites, the Autism Genetic Resource Exchange (AGRE), Simons Simplex Collection (SSC), The Danish Newborn Screening Biobank (DNSB) and The Autism Simplex Collection (TASC) one providing brain tissue, Autism BrainNet (formerly the Autism Tissue Program (ATP)).We also included two emerging bio-collections that have fewer or no publications released yet, but could be of significant impact in the future. They are the Autism Inpatient Collection (AIC) \[[@CR24]\] and the Autism Spectrum Stem Cell Resource \[[@CR25]\]. An overview of the bio-collections and their website links can be found in Table [1](#Tab1){ref-type="table"}.Table 1Information on the biobanks covered in the reviewNameFoundedLocationType of sample collected and storedWebsite/source paperAutism Genetic Resource Exchange (AGRE)1997USABlood and immortalised cell linesAGRE, [www.agre.org](http://www.agre.org)Simons Simplex Collection (SSC)2010USABlood and immortalised cell lines<https://sfari.org/resources/autism-cohorts/simons-simplex-collection>Danish Newborn Screening Bio-collection1980'sDenmarkDried blood spot samples<http://www.ssi.dk/Diagnostik/Center%20for%20Neonatal%20Screening/Den%20Neonatale%20Screenings%20Biobank.aspx>)Autism Tissue Program1998USAPost-mortem brain tissue<https://autismbrainnet.org/researchers/>Autism Spectrum Stem cell Resource2014USASkin fibroblasts, blood, induced pluripotent stem cells, neural stem cells, neuronal cells, glial cells\[[@CR25]\]The Autism Simplex Collection2010USA and EuropeBlood\[[@CR97]\]Autism Inpatient Collection2014USABlood and lymphoblasts\[[@CR24]\]

Results {#Sec6}
=======

Autism Genetic Resource Exchange (AGRE) {#Sec7}
---------------------------------------

AGRE was established in 1997 by the Cure Autism Now (CAN) Foundation and the Human Biological Data Interchange (HBDI). Samples are provided by families with children affected by ASD and are coupled with anonymously coded clinical diagnostic data, such as Autism Diagnostic Interview--Revised (ADI--R) and Autism Diagnostic Observational Schedule (ADOS). Additional clinical data include photographic dysmorphology, neurological and physical examination, and family and medical history. AGRE is currently managed by Autism Speaks. It contains over 2500 families and the resource has contributed to high profile genetic discoveries relating to ASD (Table [2](#Tab2){ref-type="table"}). Samples are housed at the National Institute of Mental Health repository at Rutgers' University in the form of immortalised cell lines, DNA and serum samples which can be accessed by researchers through applications \[[@CR20]\].Table 2Overview of studies using the AGRE collectionReferenceBio-collectionSamplesNumberStudyFindings\[[@CR35]\]AGREGenomic data (AGRE), brain tissue (mouse)4327 samples (AGRE)\
8789 samples (total)Genotype-phenotype study*HMGN1* found to be a negative regulator of *MECP2* expression. Dysregulation alters behaviour in mice, and AGRE collection contains genotypes linked to altered expression\[[@CR180]\]AGREBlood152 subjectsQuantitative trait analysisChromosome region 7q found to be a risk region for Autism Symptoms\[[@CR181]\]AGRELymphoblasts1438 subjectsAssociation study*CNTNAP2* identified as an ASD susceptibility gene\[[@CR182]\]AGREBlood1794 subjectsLinkage analysisChromosome 7q35 may harbour a gene that could contribute to variability in spoken language\[[@CR183]\]AGREGenomic data455 subjectsPedigree studyAssociation found with chromosome X region Xp22.11-P21.2, where gene *IL1RAPL1* is located and also implicated in ASD\[[@CR184]\]AGREBlood and lymphoblasts252 familiesGene expression analysis and association*ROBO1-4* found to be associated with ASD. Low expression levels of *ROBO1-2* found in ASD patients\[[@CR185]\]AGREBlood and lymphoblasts3211 subjectsGene association studyAnalysis of SNP polymorphisms in *PCDHA* suggest it as a potential candidate gene for ASD\[[@CR186]\]AGRE and ATPLymphoblasts and brain tissue3211 subjects (AGRE)\
21 subjects (ATP)Gene association study*ZNF804A* found to be associated with ASD and verbal deficits, where knockdown of this gene reduced expression of *SNAP25*, and both are reduced in the anterior cingulate gyrus in ASD brains.\[[@CR187]\]AGREBlood and lymphoblasts72 familiesAssociation studyCommon variant found in *CNTNAP2* that is linked to ASD susceptibility\[[@CR43]\]AGREBlood470 families (total) 224(AGRE)Association study*GABRB3* and *GABRG3* found to be associated with ASD\[[@CR188]\]AGREBlood and lymphoblasts975 subjectsCNV analysisAnalysis of 15q13.1-3 region revealed *APBA2* as an ASD candidate gene\[[@CR189]\]AGREBlood and lymphoblasts1577 subjects (total)\
1526 subjects (AGRE)CNV analysis*CNTNAP2* detected in ASD patients suggested to have a contribution to the disorder\[[@CR74]\]AGRELymphoblasts6 subjectsProof of principle48 genes showed differential expression between patients and controls. Many genes involved in signalling, focal adhesion and metabolism\[[@CR190]\]AGRELymphoblasts18 subjects\* (controls provided by AGRE)Profiling studyAltered levels of *UBE3A* (1.5--2 fold increase) expression found in ASD patients with 15q11-14 duplications. *APP* and *SUMO* found to be decreased, and are involved in apoptosis\[[@CR40]\]AGREBlood and lymphoblasts334 familiesReanalysis of data set using different analysis methodAssociation found in chromosome 1, which was previously overlooked. Further evidence that 17q11 is associated with ASD\[[@CR191]\]AGREGenomic data12 familiesMethod paperDescription of parent of origin method to detect mosaic chromosomal abnormalities.\[[@CR192]\]AGREBlood and lymphoblasts518 familiesReplication study and functional studyThe gene *EN2* suggested to act as ASD susceptibility locus, and mutations could alter brain development\[[@CR41]\]AGREBlood and lymphoblasts389 families (AGRE) 518 families (total)Association studyHaplotypes found in ASD families found to affect regulation of *EN2* gene expression\[[@CR75]\]AGREBlood and lymphoblasts954 subjectsGene-gene interaction studyGlutathione pathway is implicated in autism\[[@CR28]\]AGREBlood and lymphoblasts6056 subjects (TOTAL)\
4444 subjects (AGRE)GWAS*UBE3A, NRXN1, BZRAP*, and *MDGA2* found to have disruptive CNVs amongst ASD patients, some only occurring once amongst patients\[[@CR83]\]AGREGenomic data830 subjectsMethods paperUse of disease symptoms improves detection of linkage in genetic data. Useful when heterogeneity is involved\[[@CR38]\]AGREBlood18 subjectsGenotype-phenotype study3 out of 18 patients with ASD and macrocephaly had mutations in PTEN gene. Considered as ASD gene to be explored\[[@CR39]\]AGREBlood and lymphoblasts88 subjects (total)\
39 subjects (AGRE)Mutation screeningDe novo missense mutation found in one patient with ASD and macrocephaly.\[[@CR193]\]AGREBlood and lymphoblasts95 familiesGene linkage studyChromosome region 2q suggested to contain an autism susceptibility gene\[[@CR53]\]AGREBlood88 families(total)\
62 families (AGRE)Linkage analysis*GABRB3* polymorphism found to be associated with ASD\[[@CR194]\]AGREBlood115 familiesLinkage analysisAnalysis carried out for a ASD family subset with obsessive compulsive behaviours (*n* = 35) found evidence of linkage to chromosome 1 and further evidence on chromosome 6 and 19\[[@CR82]\]AGREBlood and lymphoblasts279 subjectsMethod paperMultiplex ligation-dependent probe amplification shown to be effective at detecting microduplications and deletions\[[@CR50]\]AGREGenomic data748 subjectsAssociation study*MET* variants associated with social and communication phenotypes amongst people ASD\[[@CR49]\]AGREBlood and lymphoblasts2712 subjects (total)\
631 subjects (AGRE)Association studyMultiple genes implicated in the MET pathway with ASD, such as *PLAUR* and *SERPINE1*\[[@CR48]\]AGREBlood743 families (total)\
283(AGRE)Association study*MET* promoter variant that decreases expression found to be associated with ASD\[[@CR195]\]AGREBlood and lymphoblasts109 subjectsReplication studyIndependent sample from the same cohort showed same linkage association to chromosome region 17q21\[[@CR196]\]AGREBlood480 familiesGenetic score study3 risk SNPs (*ATP2B2, PITX1, HOXA1*) had high reproducibility in males, 2 in females (*MARK1, ITGB3*), and 3 across both genders (*CTNAP2, JARID2, EN2*).\[[@CR197]\]AGREBlood381 subjectsAssociation studyAssociation between ASD in males and *ATP2B2*\[[@CR198]\]AGREBlood2569 subjectsFunctional genomics studyCombining functional genomics and statistical analysis helped identify common variants in ASD\[[@CR199]\]AGREBlood2837 subjectsAssociation studyRare haplotype affecting promoter of *DLX1* found to be associated with ASD. No common variants found for *DLX* genes and *GAD1*\[[@CR200]\]AGREBlood2261 subjectsGWASThe chromosome regions Xp22.33/Yp11.31 suggested to harbour male specific variants for ASD\[[@CR201]\]AGREBlood1132 subjectsQTL analysisChromosome regions 16p12-13 and 8q23-24 linked to harbour genes contributing to deficits in non-verbal communication in autistic patients\[[@CR202]\]AGREBlood993 subjectsAssociation studyGlu27 allele of *ADRB2* gene suggested to confer increased risk of autism, with pregnancy related stressors having an increased effect\[[@CR203]\]AGREBlood and brain tissue90 subjectsGene identificationIdentification of the gene CORTBP2 from autism candidate region 7q31\[[@CR54]\]AGREBlood611 familiesAssociation studyReinforced evidence that GABRA4 and GABRB1 are implicated in ASD. Other ethnic groups found to have SNPs in these genes\[[@CR204]\]AGREBlood228 families (total)\
38 (AGRE)Association study*HOXG1* polymorphism A218G found to be associated in increased head circumference amongst ASD patients\[[@CR205]\]AGREGenomic data2165 subjects + 1165 families (total)\
2165 subjects (AGRE)GWASAssociations found in the following genes with ASD and linked co-morbidities; *KCND2*, *NOS2A* and *NELL1*\[[@CR206]\]AGREDNA37 twin sets (total)\
15 twin sets (AGRE)Association studyTerbutaline exposure for two or more weeks associated with increased concordance for ASD. 2 polymorphisms for *ADRB2* associated with ASD\[[@CR207]\]AGREBlood284 families (total)\
38 families (AGRE)Linkage/association studyVariants of *PON1* found to be associated with ASD families in North America, but not in Italian families\[[@CR208]\]AGREBlood38 subjectsCNV studyMicrodeletions and duplications on chromosome regions 3p26.3, 6q24, 22q11.2, 4q34.2 and 1q24 linked to ASD with physical anomalies. Genes *STXBP5* and *LRRN1* identified as candidate genes\[[@CR209]\]AGRE\
SSCGenomic data2294 subjects (SSC)\
579 subjects (AGRE)\
35663CNV analysisExploration of evolution of human specific *SRGAP2* genes. Rare duplications observed in SSC cohort for *SRGAP2C*.\[[@CR210]\]AGREGenomic data from \[[@CR211]\]121 familiesQTL-analysis2 loci were identified in chromosomes 11 and 17 associated with social responsiveness in ASD families\[[@CR81]\]AGREBlood411 families (total)\
371 families (AGRE)Method paperDetection of amplicons using mismatch repair. More amplicon variants were found in patients compared to controls\[[@CR212]\]AGREBlood66 subjectsMetabolite analysisASD families have lower levels of unprocessed Reelin protein in blood than controls\[[@CR213]\]AGREBlood90 subjectsGene characterisation*CADPS* and *CADPS2* characterised and cloned. Found to be activators of protein secretion. No disease specific variants found amongst ASD patients\[[@CR214]\]AGREGenomic data1146 subjectsLinkage analysisLinkage peaks found for language---speech phenotypes consistent with potential motor speed disorder in following chromosome regions; 1q24.2, 3q25.31, 4q22.3, 5p12, 5q33.1, 17p12, 17q11.2, 17q22, 4p15.2 and 21q22.2. multiple candidate genes were also identified\[[@CR215]\]AGREBlood2140 subjectsLinkage analysisParental origin effect significantly linked to chromosomes 4, 15 and 20\[[@CR42]\]AGREBlood167 familiesAssociation study*EN2* found to be associated with ASD susceptibly\[[@CR216]\]AGREBlood and lymphoblasts537 subjects (total)\
34 subjects (AGRE)CNV analysisProposal that increased CNV load, particularly duplication of base pairs, predisposes to ASD. Negative correlation found with CNV load and social and communication skills. Applied to both common and rare CNVs\[[@CR73]\]AGREBlood and lymphoblasts4714 subjects (total)\
1336 subjects (AGRE)CNV analysisGenes involved in Neuronal adhesion (*NLGN1, ASTN2*) and ubiquitin pathways (*UBE3, PARK2, RFWD2, FBXO40*) were found in ASD patients. Further evidence of *NRXN1* and *CNTN4* involved with ASD.\[[@CR217]\]AGREBlood147 subjectsGenotype phenotypeSuggested relationship between polymorphism *MTFR* 677C → T and autism-related behaviours\[[@CR218]\]AGREBlood and lymphoblasts693 subjects (AGRE)\
5878 subjects (total)CNV analysisMicroduplications and microdeletions in chromosome 16p11.2 associated with psychiatric disorders; duplications associated with schizophrenia, bipolar disorder and ASD, and deletions with ASD and other neurodevelopmental disorders\[[@CR219]\]AGREBlood219 subjectsVariant analysis*DLX1/2* and *DLX5/6* gene analysis may not contribute to ASD but functional analysis of variants still worth investigation\[[@CR36]\]AGREBlood1410 (total)\
401 (AGRE)Association studyNo association found for a sequence variant in mental retardation found in exon 1 of MECP gene in autism cohort\[[@CR220]\]AGREBlood and lymphoblasts112 families(total)\
79 families (AGRE)Association studyA haplotype for *DRD1* is found to be associated with ASD risk amongst males\[[@CR221]\]AGREData from \[[@CR222]\]551 subjects (AGRE)SNP analysisAnalysis of SNPs revealed variants of *CD38* associated with ASD. Variants of *CD38* linked to control of OXT secretion.\[[@CR223]\]AGRELymphoblastoid cell14 subjectsGene expression analysisFirst study to show differential expression between lymphoblastoid cell lines. Genes affected implicated in cell death and development, nervous system development and immune development and function\[[@CR224]\]AGRELymphoblasts116 subjectsGene expression analysisPatients with severe ASD showed altered expression of genes involved in Circadian rhythm. 20 novel genes found putative non-coding regions associated with androgen sensitivity\[[@CR225]\]AGREGenomic data1295 families (total)\
696 families (AGRE)GWASNoise reduction filter for GWAS leads to list of 830 candidate genes, where they impact dendrite and axon outgrowth and guidance\[[@CR29]\]AGRE ATPBlood and brain133 sib pairs (total) 77 Sib pairs (AGRE) 17 brain tissue (ATP)Ogliogenic hypothesis studyEvidence of epigenetic and genetic factors possibly contributing to ASD and *UBE3* having a possible role in ASD\[[@CR179]\]AGREBlood and lymphoblasts192 subjects (AGRE)\
483 subjects (total)Association studyDisruptions in *NRXN1* gene found to be associated with ASD\[[@CR226]\]AGREGenomic data476 subjects (total)\
290 subjects (AGRE)Association studySuggestive association of parent and maternal origin effect on *SLC6A4* promoter variant and ASD. Further testing required on biological model or larger cohort\[[@CR26]\]AGREBlood and lymphoblasts1549 subjects\
410 subjects (AGRE)Mutation screeningRecurrent microdeletions in chromosome region 16p11.2 were observed in ASD patients and not in controls\[[@CR227]\]AGREBlood and lymphoblasts974 subjects (total)\
512 subjects (AGRE)Mutation screening*RIMS3* identified as a possible ASD susceptibility gene\[[@CR228]\]AGREBlood33 families (AGRE)\
49 families (total)Association studyAssociation found for *HLA-DR4* gene in higher frequency in geographically defined subtype, but not in controls or AGRE sample\[[@CR229]\]AGREBlood508 families (total)\
139 families (AGRE)Association studyAnalysis of 2p15-16.1 microdeletions region identified two candidate genes; *XPO1* and *OXT1*\[[@CR230]\]AGREBlood and lymphoblasts407 families (total)\
138 familiesAssociation analysisPolymorphisms found in or near *DLX1* and *DLX2* found to be associated with ASD\[[@CR231]\]AGREBlood and lymphoblasts512 families (total) 138 families (AGRE)Association studyAssociation found between ASD and *MTHFR* gene in simplex families but not in multiplex families\[[@CR37]\]AGREBlood and lymphoblasts219 families (total)\
98 families (AGRE)Association studyPolymorphisms in *MECP2* found to be associated with ASD\[[@CR232]\]AGREGenomic data990 familiesAssociation study2 genes found to be associated with ASD; *RYR2* and *UPP2*\[[@CR233]\]AGREGenomic data2194 families (total)\
543 families (AGRE)Association studyAssociation found between the calcium channel genes (*CACNA1L*, *CACNA1C* and *CACNA1*) with ASD\[[@CR32]\]AGREBlood470 families (total)\
224 families (AGRE)Gene association studies*GABRA4* and *GABRB1* found to be associated with ASD\[[@CR234]\]AGREGenomic data680 families (AGRE) 1167 families (total)GWASIdentification of a common novel risk locus as chromosome region 5p14.1. Common and rare variants identified. AGRE used as validation dataset\[[@CR75]\]AGRELymphoblasts12 subjectsCell necrosisCells from autistic patients were more susceptible to oxidative and nitrosative stress\[[@CR235]\]AGREBlood and lymphoblasts1142 subjects (total)\
139 families (AGRE)Association study*GTF2i* found to be associated with ASD\[[@CR236]\]AGREBlood and lymphoblasts207 familiesCNV analysisTranslocation between short arms of chromosome 16 and 15 reported in 1 female patient. Nominal association of *A2BP1/FOX1* observed in ASD cohort.\[[@CR237]\]AGRESerum21 human subjects\
13 rhesus monkeysExposure studyMonkeys exposed to antibodies from human mothers of autistic children displayed stereotypies and hyperactive behaviour. Autoimmune component suggested to contribute to ASD\[[@CR238]\]AGRE\
ATPBlood, lymphoblasts and brain tissue276 families (AGRE)\
17 subjects (ATP)Association study*MARK1* gene found to be associated with ASD. Overexpression of gene also found in prefrontal cortex (BA46) but not cerebellum in human post-mortem tissue. Mouse model showed abnormalities in dendrites.\[[@CR55]\]AGREBlood123 families (total)\
75 Families (AGRE)Linkage disequilibrium studyNominal evidence found for ASD risk alleles in GABA~a~ Receptor subunits\[[@CR52]\]AGREBlood137 families (total)\
80 families (AGRE)Linkage and association study*SLC6A4* found not to be associated to rigid-compulsive subset of ASD patients.\[[@CR239]\]AGREBlood158 families (total)Linkage analysisIncreased support that chromosome regions 19p13 and 17q11.2 harbour ASD susceptibility loci\[[@CR240]\]AGREBlood and lymphoblasts1336 subjects (AGRE)\
1509 subjects (total)CNV analysisLarge-scale survey of 15q24 microdeletion syndrome identifies atypical deletion that narrows critical region and (776 kb versus 1.75mb) and number of genes (15 versus 38) sequencing of genes recommended\[[@CR241]\]AGREGenomic data4278 subjects (total)\
1518 subjects (AGRE)Transmission disequilibrium testingAGRE dataset found to have a genome wide signals at chromosome region 10q26.13 in both sexes and paternal signals in 6p21.1\[[@CR30]\]AGREBlood and lymphoblasts2886 subjects (total)\
1441 subjects (AGRE)CNV analysisMicrodeletions and duplications at chromosome region 15q13.2q13.3 found to be associated with ASD symptoms and other psychiatric disorders\[[@CR242]\]AGREBlood and Lymphoblasts34 subjectsLinkage analysis studyChromosomes 7q and 21q are associated with a subset of ASD patients with developmental regression\[[@CR222]\]AGREBlood and brain tissue1221 subjects (total)\
263 subjects (AGRE)Association studyTwo genetic variants of *CD38* found to be associated with ASD\[[@CR243]\]Blood233 subjectsAssociation studyHOXA1 A218G alleles found to significantly influence head growth rates.\[[@CR244]\]AGREBlood196 familiesAssociation studyAssociation not found between SNPs in *DLX6* and *PLCO* on chromosome 7q21-22 and ASD\[[@CR245]\]AGREBlood196 familiesAssociation studyPresence of a susceptibility mutation found in *TDO2* or nearby gene\[[@CR246]\]AGREBlood and lymphoblasts249 familiesAssociation studyElevated levels of *STX1A* found to be associated with ASD\[[@CR47]\]AGRE and ATPLymphoblasts14 subjects (AGRE)\
84 subjects (ATP)Methylation studyDifferent methylation patterns found for genes involved in cell death/survival, neurodevelopment and gene transcription. Decreased expression of *RORA* and *BCL2* was found in brain samples of ASD patients\[[@CR247]\]AGREBlood and lymphoblasts110 subjectsGenetic association studyAssociation found between *PER1* and *NPAS2* and ASD\[[@CR248]\]AGREBlood and lymphoblasts104 familiesGenetic association study*BDNF* associated with ASD; significantly higher expression in ASD subjects\[[@CR249]\]AGREBlood and lymphoblasts13,205 subjects (total)\
80 subjects (AGRE)CNV analysisDisruption of the *PTCHD1* locus on Xp22.11 identified in families with ASD and in families with Intellectual disability. Novel CNVs identified in *DPYD* and *DPP6*.\[[@CR80]\]AGRE and ATPLymphoblasts and brain tissue13 subjects (AGRE)\
3 subjects (ATP)Genotype-phenotype studyIncreased dosage of the gene *CYFIP1* results in altered cellular and dendritic morphology and dysregulates mTOR pathway in ASD patients with duplications in 15q11-13\[[@CR250]\]AGREBlood and lymphoblasts95 subjects (AGRE)\
134 subjects (total)Genomic and molecular studyNo coding mutations or parental-specific expression found in ASD and Gilles de la tourettes syndrome (GTS) in the gene *IMMP2L*. Gene should not be written out as factor for both conditions\[[@CR251]\]AGREBlood and lymphoblasts283 familiesLinkage mapping study*PRKCB1* shown to be associated with ASD\[[@CR252]\]AGREBlood and lymphoblasts1086 subjectsCandidate gene study*PITX1* shown to be associated with ASD\[[@CR253]\]AGREBlood406 families (total)\
99 Families (AGRE)Association and linkage disequilibrium study*GAD1* SNPs found not to be associated with ASD\[[@CR254]\]AGREBlood322 families (total)\
86 families (AGRE)Association studyNo association found with *APOE* gene and ASD.\[[@CR255]\]AGREGenomic data4530 subjectsAssociation studyImmune function genes *CD99L2*, *JARID2* and *TPO* show association with ASD\[[@CR256]\]AGREBlood and lymphoblasts334 familiesAssociation studyAnalysis of 2q24-q33 region found following genes associated with ASD; *SLC25A12, STK39* and *ITGA4*\[[@CR257]\]AGREBlood and lymphoblasts411 families (total)\
371 families (AGRE)Linkage analysisLinkage analysis of SNPs suggests *SLC25A12* to be associated with ASD\[[@CR258]\]AGREBlood and lymphoblasts352 familiesAssociation studyNo association found between polymorphisms in TPH1 and TPH2 and ASD susceptibility or endophenotypes\[[@CR259]\]AGREBlood and lymphoblasts352 families (total)\
295 families (AGRE)Association studyNo association found between *SLC6A4* variants and susceptibility to ASD\[[@CR260]\]AGREBlood and lymphoblasts1011 subjectsAssociation study*AHI1*, a gene associated with Joubert Syndrome, is also implicated in ASD\[[@CR261]\]AGREGenomic data2883 individualsMethods paperTool that provides visualisation of SNP data\[[@CR262]\]AGRESerum34 subjectsMetabolite studyASD patients had lower levels of the enzyme AAT in serum compared to controls. Difference is much more significant in ASD patients with regressive onset\[[@CR263]\]AGREBlood and lymphoblasts486 subjects (total)\
252 subjects (AGRE)Genotype-phenotype studyMice with *CADPS2* knockout display autistic-like behaviour and cellular features. Analysis of human Cadps2 mRNA revealed aberrant splicing that resulted in some patients lacking exon 3 of the transcribed gene\[[@CR264]\]AGREBlood and genomic data860 subjects (total)\
468 subjects (AGRE)GWASRegions in 5q21.1 and 15q22.1-q22.2 found to have most significant association in combined data for Asperger. 8 regions overlap with ASD linkage areas, and 3 overlapped with a Finnish cohort\[[@CR79]\]AGRELymphoblasts14 subjectsMicroRNA analysisDysregulation of MicroRNA expression contributes to gene expression in ASD. Gene targets *ID3* and *PLK2* were validated by knockdown and overexpression assays\[[@CR265]\]AGREGenomic data289 familiesMethod paperSNPs involved in three-way epistatic interactions found and all located in gene GLRX3\[[@CR58]\]AGREBlood and lymphoblasts264 familiesCNV analysisDe novo CNVs were found to be strongly associated with Autism\[[@CR266]\]AGREBlood and lymphoblasts248 subjects (total)\
146 subjects (AGRE)Association studyResults suggestive that a y-chromosome haplotype effect is associated with ASD\[[@CR267]\]AGREBlood and lymphoblasts196 familiesTransmission analysisPolymorphisms in *INPP1*, *PIK3G* and *TSC2* found to have linkage disequilibrium in ASD subjects\[[@CR268]\]AGREBlood and lymphoblasts196 familiesTransmission analysisSuggestive evidence that *GRM8* is a susceptibility gene in ASD\[[@CR269]\]AGREBlood and lymphoblasts196 familiesAssociation studySuggestive but tentative evidence for *MTF1* and *SLC11A3* as ASD suspectability genes\[[@CR270]\]AGREBlood and lymphoblasts10 subjectsWhole genome sequencing59 candidate genes suggested to be associated with ASD susceptibility, with *ANK3* being the top result. 33 non-coding variants were also identified.\[[@CR271]\]AGREGenomic data \[[@CR73]\]1336 subjectsMethod paperCNV analysis method that uses both B-allele frequency and log R ratio to find CNVs. Found all 21 validated short duplications in AGRE dataset. Analysis is much faster.\[[@CR272]\]AGREBlood and lymphoblastsData taken from Ramoz, 2004Association studySuggestive association found for ASD-related routines and rituals with a polymorphism in *SLC25A12*\[[@CR273]\]AGREBlood and lymphoblasts144 subjectsSequencing study7 rare variants found in *NLGN3* and *NLGN4X*. UTR found not to be significant. 2 intronic variants suggested to influence regulation of genes. Limited by throughput and cost\[[@CR274]\]AGREBlood351 familiesAssociation studyNominal significance found for 15 genes, top 3 being *MYO1D*, *ACCN1* and *LASP1* suggested for further study\[[@CR275]\]AGREGenomic data148 familiesLinkage analysisMale-specific linkage mapped to chromosome 17q11. Evidence of sex specific risk alleles in ASD\[[@CR56]\]AGRELymphoblasts284 subjectsAssociation study*CACNAG* identified as a candidate gene for ASD\[[@CR276]\]AGRELymphoblasts267 subjects (AGRE)Linkage and association study*SLC6A4* shown to contribute to ASD susceptibility\[[@CR78]\]AGRELymphoblasts12 subjectsMicroRNA studyLymphoblastoid cell lines from ASD patients can be used to assess microRNAs in ASD. Dysregulated MicroRNAs found to target genes linked to ASD\[[@CR277]\]AGREBlood samples100 subjectsCholesterol metabolism20% of the samples have shown hypercholestolemia, indicating that cholesterol metabolism could be perturbed in ASD\[[@CR278]\]AGREGenomic DNA756 subjectsAssociation study*EGF* found to have significant association with ASD\[[@CR279]\]AGRE and ATPData mining (AGRE) brain tissue (ATP) and blood83 subjectsLinkage study3p26.1, 3p26.3, 3q25-27 and 5p15 enriched for differentially expressed genes in blood and brain tissue. *CNTN4, CADPS2, SUMF1*, *SLC9A9* and *NTRK3* implicated in ASD and even more genes involved in neurological disorders that are co-morbid with ASD\[[@CR280]\]AGREBlood97 familiesExpression profile analysis*RAY1/ST7* locus found to contain a multi-transcript system. Screening of ASD patients found rare variants not present in controls\[[@CR281]\]AGREBlood and lymphoblasts196 families (total)\
95 families (AGRE)Mutation screeningNo mutations found in coding regions of X-chromosomal *NLGN* genes.\[[@CR282]\]AGREBlood and lymphoblasts136 families (total)\
96 families (AGRE)Association studyHigh association of *FMR1* gene variant found amongst east Asian individuals, but not when whole sample was analysed, stratification confounded result\[[@CR283]\]AGRELymphoblasts11 subjectsNeurotoxicityBoth ASD patients and controls showed upregulation of heat shock proteins when expressed to thimerosal\[[@CR33]\]AGREBlood and lymphoblasts3101 subjects (AGRE)\
10796 subjects (total)GWASGenome-wide SNPs found in *CDH10* and *CDH9* found to be associated with ASD\[[@CR284]\]AGRE\
ATPBlood, lymphoblasts and brain tissue1031 families (AGRE)\
3104 families (total)\
30 subjects (ATP)GWASAnalysis found association in chromosome region 5p15, where genes *SEMA5A* and *TASR2* are located. Analysis of brain tissue showed reduced expression of *SEMA5A* in ASD subjects\[[@CR27]\]AGRELymphoblasts5675 subjects (AGRE)Association studyMicro deletion found in chromosome 16p11.2. amongst AGRE, Boston Children's Hospital and Icelandic population data sets\[[@CR57]\]AGREBlood229 familiesAssociation studySodium channel genes *SCN1A1-3* contained SNPs of interest amongst ASD families for future studies\[[@CR285]\]AGREBlood564 families (total)\
327 families (AGRE)\
genetic analysis only\
261 subjects (serotonin analysis)Association study*ITGB3* genetic variation found to be associated with serotonin blood levels and ASD susceptibility\[[@CR286]\]AGREGenomic data5328 subjectsRecurrence rate studySignificant difference in recurrence rates between male only families and female carriers in regard to ASD. Female protective effect suggested to be at work in high genetic-risk families involving female carriers. Shorter interbirth intervals correlated to ASD risk.\[[@CR287]\]AGREBlood lymphoblasts1587 subjectsLinkage analysisReplication of linkage on 20p13. Linkage found for chromosomes 6q27, 8q13.2, 1p31.3, 8p21.2 and v8p12\[[@CR288]\]AGRELymphoblasts75 subjects (total)\
50 subjects (AGRE)Gene characterisationGene characterised and assessed for mutation amongst ASD patients. No concrete association found\[[@CR289]\]AGREGenomic data487 familiesMethod paperPathways of interest analysed using GWAS SNP data. 5 pathways shown to be of significance in regards to ASD\[[@CR290]\]AGREBlood and lymphoblasts383 subjectsLoci analysisAGRE and Finnish ASD dataset both showed strong association with 3p24-26 locus containing the gene *OXTR*\[[@CR211]\]AGREBlood and lymphoblasts833 familiesGenome-wide screenEvidence of linkage to ASD found on chromosomes 17, 5, 11, 4 and 8, of which 17 having the highest association score in the group\[[@CR291]\]AGREBlood and lymphoblasts110 familiesGenome-wide linkage analysisNominal evidence for linkage found in chromosomes 2--4,8, 10--12,15-16,18 and 20. significant linkage found for chromosomes 5 and 8 after reanalysis\[[@CR292]\]AGREBlood and lymphoblasts389 familiesAssociation studyNo evidence found that RH -ABO foetal-maternal incompatibility is associated with ASD\[[@CR46]\]AGREBlood126 families (total) 81 families (AGRE)Association study*RELN* alleles with large CGG repeats may play a role in aetiology of certain ASD cases\[[@CR293]\]AGREBlood and lymphoblasts165 subjectsPopulation geneticsStudy suggested two groups: low risk families caused by spontaneous mutations, and high risk caused by female offspring that carry ASD-causing mutation that is passed onto their own offspring\[[@CR294]\]AGREBlood and lymphoblasts205 familiesGene association studyNo association found between ASD and variant of the gene *EN2*\[[@CR295]\]AGRELymphoblasts20 subjectsIntracellular redox studyInbalance of glutathione redox in cell lines derived from patients with ASD\[[@CR76]\]AGRELymphoblasts86 subjectsTransmethylation/transsulfuration studyCell lines derived from parents of ASD children showed abnormal transmethylation/transsulfuration metabolism and DNA hypomethylationStudy numbers listed as families or subjects wherever applicable

The AGRE resource has been used extensively in genomics studies in ASD. Approaches have included gene-mapping such as genome-wide linkage and association studies in addition to studies of chromosomal structure, particularly the identification of copy number variants. Important ASD chromosomal regions identified include microdeletions and microduplications of 16p11.2 \[[@CR26], [@CR27]\], rearrangements and microdeletion/duplication of 15q13.2q13.3 \[[@CR28]--[@CR31]\], common variants in the 5p14.1 region \[[@CR32], [@CR33]\], Neurexins and 11p12--p13 \[[@CR34]\].

It has also helped in identification of recurrent candidate genes, such as *MECP2* \[[@CR35]--[@CR37]\], *PTEN* \[[@CR38], [@CR39]\], *EN2* \[[@CR40]--[@CR42]\], *RELN* \[[@CR40], [@CR43]--[@CR46]\], *RORA* \[[@CR47]\], *MET* \[[@CR48]--[@CR50]\], *NGLN3-4* \[[@CR51]\], *BZRAP1* \[[@CR28]\], *SLC6A4* \[[@CR40], [@CR52]\] GABA receptors \[[@CR32], [@CR43], [@CR53]--[@CR55]\], CACNA1G \[[@CR56]\] and the sodium channel genes *SCN1A*, *SCN2A* and *SCN3A* \[[@CR57]\].

These studies particularly highlighted an important role of de novo and large inherited copy number variations (CNVs), which are detected in 10% of sporadic ASD \[[@CR58]\], which has been widely replicated in other bio-collections \[[@CR59]--[@CR71]\]. The use of AGRE combined with other AGP resources have uncovered *SHANK2*, *SYNGAP1*, *DLGAP2* and the X-linked *DDX53-PTCHD1* locus as novel ASD genes, as well as pathways of cellular proliferation, signalling, neuronal projection and motility \[[@CR72]\]. AGRE samples formed a replication set in a separate analysis highlighting CNVs of neuronal cell adhesion and ubiquitin pathway in ASD \[[@CR73]\].

AGRE lymphoblastoid cells enabled studies into shared ubiquitin and neuronal gene expression in lymphoblastoid cells and brain \[[@CR73], [@CR74]\], gluthathione metabolism, oxidative stress \[[@CR75], [@CR76]\] and stress response \[[@CR77]\], microRNAs and their use in ASD profiling \[[@CR78], [@CR79]\], *CYFIP1* dosage effect on mTOR regulation \[[@CR80]\], and changes in methylation patterns of *RORA* and *BLC2* and their effects on apoptosis, cellular differentiation, inflammation and neural development \[[@CR47]\].

The AGRE collection was also used to establish genetic methodologies and bioinformatic tools. This included using mismatch repair to detect amplicons in ASD \[[@CR81]\], using multiplex ligation-dependent probe amplification (MPLA) to improve detection of microduplications and microdeletions \[[@CR82]\], and incorporating disease symptoms to improve linkage detection in genetic data \[[@CR83]\] and analysis of genetic loci to search for candidate genes \[[@CR84]\].

Simons Simplex Collection (SSC) {#Sec8}
-------------------------------

The SSC is a genetic and clinical repository, which contains material derived from 2600 families. Whereas the AGRE contains multiplex families and trios, The SSC ascertained "simplex" ASD families defined as families where only one child has ASD and at least one other typically developing sibling. DNA is available for both parents, the affected child and an unaffected sibling. Thus the SSC samples are particularly valuable in evaluating parental inheritance. Samples were collected at multiple sites and were stored as immortalised cell lines at Rutgers University Cell and DNA Repository (RUCDR). Each sample was verified for parentage, gender and Fragile X mutation. In-depth clinical phenotypes were characterised for all participants to support genotype-phenotype analyses. These included data on diagnostic status, medical and psychiatric comorbidity, family history and medication use for the affected person. Broader ASD phenotype measures were collected for unaffected family members.

The SSC has become a vast resource of ASD and contributed significantly to numerous Whole exome sequencing studies of ASD in the past \~7 years (Table [3](#Tab3){ref-type="table"}). The main findings showed that de novo mutations were frequently enriched in ASD patients \[[@CR60]\]. Whole-genome sequencing results showed a significant enrichment of de novo and private disruptive mutations in putative regulatory regions of previously identified ASD risk genes. It also identified novel risk factors of *CANX*, *SAE1* and *PIK3CA* with small CNVs and exon-specific SNPs, which were overlooked in previous CNV studies or exon sequencing \[[@CR85]\]. It has also been observed that many de novo mutations were of paternal origin (4:1) and positively correlated with paternal age, \[[@CR65]\]. The disruptive mutations were located in genes involve in transcription regulation, chromatin remodelling and synapse formation \[[@CR86], [@CR87]\].Table 3Overview of studies using the SSC collectionReferenceBio-collectionSamplesNumberStudyFindings\[[@CR296]\]SSCGenomic data2760 subjectsCNV analysisNo association found between conception-assisted reproduction and risk of ASD\[[@CR297]\]SSCLymphoblasts900 subjectsSequencing studyRare functional variants of *TSC1/TSC2* did not show association with ASD\[[@CR298]\]SSCGenomic data965 subjects (SSC)Integrative analysisIntegrative analysis of data from 4 exome sequencing studies revealed enrichment of genes involved in chromatin remodelling and transcription in ASD patients\[[@CR88]\]SSCBlood3730 subjectsGenotype-phenotypeSubtype of autism was caused by mutations to *CHD8*, of which 15 were found.\[[@CR299]\]SSCBlood259 subjectsCNV analysisPaired duplications mark cryptic inversions and other complex structural variations in CNV data.\[[@CR300]\]SSCBlood552 subjects (total)\
412 subjects (SSC)Transcriptome analysisNeuron development, nitric oxide signalling, neurogenesis and skeletal development were found outliers amongst ASD patients in TGEN cohort, whereas outliers were found in neurogenesis in ASD patients from SSC cohort\[[@CR301]\]SSCBlood and lymphoblasts99 familiesCNV analysis55 potential pathogenic CNVs were identified and validated. 20% were considered rare when compared to the database of genomic variants. CNVs found in lymphoblast DNA but not in blood, suggesting pre-existing mutations may have been present in initial lymphoblast cells\[[@CR302]\]SSC\
AGREBlood urine12600 subjects (total)\
1887 subjects (SSC)\
752 subjects (AGRE)Association study*TMLHE* found to have high levels of deletion in male-male multiplex families (1 in 190) and deficiency of this gene could be a susceptibility factor for ASD.\[[@CR303]\]SSCGenomic and exomic dataTaken from earlier studies \[[@CR60], [@CR61], [@CR70]\]Genotype-phenotype studyMutations in ASD candidate genes have greatest impact on pyramidal neurons, cortical neurons and medium spiny neurons. Truncating de novo mutations play a small role in high-functioning cases. The greater the functional disruption of genes, the more severe the phenotypes are.\[[@CR304]\]SSCBlood2575 subjectsGWASReducing phenotypic heterogeneity within the cohort did not have a significant effect on increasing genetic homogeneity.\[[@CR305]\]SSC\
AGREBlood14989 subjects (total)\
5981 subjects (AGRE)\
1815 subjects (SSC)GWASCNVs found in *SEMA5* regulated gene network found to be associated with ASD\[[@CR86]\]SSCBlood13,804 subjectsWES104 genes were implicated in 5% of ASD cases, where they are involved in transcription, chromatin remodelling and synapse formation.\[[@CR59]\]SSCBlood2963 subjectsWESDe novo INDELS primarily originate from father, frameshift INDELS associated with ASD, Frameshift INDELS more frequent in females. RIMS1 and KMT2E found to be associated with ASD\[[@CR306]\]SSCBlood8 subjectsMethods PaperWGS data more effective than WES for detection of INDELS. x60 sequencing required to recover 95% of detected Indels\[[@CR307]\]SSCGenomic data2066 subjectsHomozygosity studyIn ASD simplex families, increased runs of homozygosity is associated with Intellectual disability\[[@CR308]\]SSCBlood1227 subjects (total)\
350 subjects (SSC)CNV analysisCNV burden correlates to certain disorders; high CNV burden to Intellectual disability and low CNV burden to dyslexia\[[@CR178]\]SSC\
AGREBlood3168 subjects (total)\
2478 subjects (SSC)\
719 subjects (AGRE)Rearrangement hotspot study1q21 duplications found to be associated with Autism. CNVs identified in *CHD1L*, *ACACA*, *DPP10*, *PLCB1*, *TRPM1*, *NRXN1*, *FHIT* and HYDIN enriched in ASD. Duplications linked to decreased non-verbal IQ and duplications linked to severity of ASD.\[[@CR149]\]SSCIPSCs and lymphoblasts1041 subjectsDisease modelling studyDisruption of *TRPC6* causes disruption in human neurons and linked to a non-syndromic form of ASD. First Study to use Patent-derived IPSCs to model non-syndromic form of ASD\[[@CR309]\]SSC\
AGREBlood2975 subjects (total)\
1429 subjects (SSC)\
14 subjects (AGREGWAS sequencingRare variants in synaptic genes associated with ASD. Loss of function in candidate genes a major risk factor for ASD.\[[@CR310]\]SSC\
TASCBlood932 families (total)Method paperTransmission and de novo association(TADA) is a method that incorporates WES data, as well as inherited variants, and variants identified between cases and controls\[[@CR311]\]SSCExome data597 subjectsMethod descriptionAssociation was found between ASD and rare variants of the gene *ABCA7* in exome data\[[@CR312]\]SSCBlood15479 subjects (total)\
9479 subjects (SSC)Transmission analysisDemonstration that high and low IQs could be distinguished by LGD load in respective gene targets. Transmission of rare variants with low LGD load occurs more often to affected offspring. Biased transmission towards children with low IQ\[[@CR61]\]SSCBlood1478 subjectsWESGene disrupting mutations were twice as frequent in ASD subjects compared to controls. Genes disrupted were associated with Fragile X Protein FMRP.\[[@CR121]\]SSCBlood762 subjectsCNV studyFemale subjects showed a higher mutational burden before developing ASD.\[[@CR313]\]SSCBlood720 subjectsAssociation studyAssociation was found between gene *SLC25A12* and restricted and repetitive behaviour.\[[@CR314]\]SSCBlood2106 families (TOTAL)\
965 families(SSC)Common variation studyMultiple common variants of genes additively contribute to ASD risk. Simplex families found to closely follow additive model compared to multiplex families\[[@CR315]\]SSCBlood285 subjectsTranscriptomic studyEnriched genes found in long term potentiation/depression, Notch signalling and neurogenesis amongst ASD Patients. 55 gene prediction model performed well on male subjects, but not female subjects\[[@CR316]\]SSCBlood58 subjectsTranscriptomic studyUpregulation of spliceosome, mitochondrial and ribosomal pathways and downregulation of neuroreceptor-ligand, immune response and calcium signalling pathways in ASD patients compared to controls\[[@CR317]\]SSCGenomic data78349 subjects (total)\
3080 subjects (SSC)SNP study17--29% of variance in liability explained by SNPS. Genetic correlation found between disorders;\
High: Schizophrenia and bipolar disorder\
Moderate: Schizophrenia and major depressive disorder, major depressive disorder and ADHD, major depressive disorder and bipolar disorder\
Low: Schizophrenia and ASD\[[@CR60]\]SSCGenomic Data1784 subjectsCNV studyDe novo duplications and deletions are major contributors to ASD. Females shown to have a greater genetic resistance to autism.\[[@CR318]\]SSC\
AGRE\
TASCBlood6970 subjects (total)\
806 subjects (AGRE)\
996 subjects (TASC)\
563 subjects (AGRE)WES2-fold enrichment of complete knockout of autosomal genes with low LoF variation, and 1.5-fold enrichment for rare hemizygous knockout in males. Both contribute 3 and 2% to ASD risk, respectively.\[[@CR63]\]SSCLymphoblasts386 subjectsCNV studyRecurrent and rare de novo CNVs were discovered to alter gene expression in chromosome regions 3q27, 3p13, 3p26, 2p15, 16p11.2 and 7q11.23.\[[@CR129]\]SSCIPSCs12 subjectsDisease modellingOverexpression of *FOXG1* was linked to increased head circumference and ASD severity in idiopathic autism subjects. An overabundance of inhibitory neurons in ASD cell lines was also found.\[[@CR319]\]SSCGenomic and clinical data2478 subjectsGene-environment studyIndividuals with ASD-associated CNVs were more susceptible to effects of febrile episodes and maternal infection during pregnancy and have impact on behavioural outcomes\[[@CR320]\]SSCBlood10118 (TOTAL)\
1974 (SSC)Genetic associationHigher prevalence of *SLC12A5* variants containing altered CpG sites amongst ASD patients.\[[@CR321]\]SSC\
DNSBBlood2418 subjects (SSC)\
1353 subjects (DSNB)CNV analysis17q12 deletion identified as a CNV variant that confers high risk of ASD and Schizophrenia\[[@CR322]\]SSC\
AGREGenomic data49167 subjects (total)\
1124 subjects (SSC)\
1835 subjects (AGRE)CNV analysisMore significant CNVs that could infer ASD risk were identified using combined large clinical datasets of neurodevelopmental disorders than with ASD cohorts alone\[[@CR323]\]SSCLymphoblasts5451 subjectsAssociation studyNo association was found for heterozygous mutations in *CNTNAP2* and contribution to ASD risk\[[@CR324]\]SSCBlood and lymphoblastoid cell lines593 familiesMethod descriptionA novel method was used to detect de novo and transmitted insert-deletions(Intel's) in exomic data\[[@CR325]\]SSCBlood1315 subjects (total)\
145 subjects (SSC)CNV analysisDuplication CNVs enriched in negative regulation categories, deletion CNVs enriched in positive regulation categories. Highly connected genes in network enriched in patients with a single gene CNV change\[[@CR65]\]SSCBlood677 subjects (SSC)WESDe novo mutations paternal in origin (4:1) and positive correlation with age. Recurrent mutations in genes *CDH8* and *NTNG1*.\[[@CR64]\]SSCBlood20 families (total)\
19 families(SSC)WES21 de novo mutations identified. 11 of which found to be protein altering. Mutations identified in *FOXP1, GRIN2B, SCN1A, LAMC3* and *CNTNAP2.*\[[@CR87]\]SSCBlood2246 subjects (SSC)WES27 de novo events found in 16 genes, 59% predicted to truncate proteins. further support for genotype-phenotype relationship in *CDH8* and *DYRKA1*\[[@CR326]\]SSCBlood19 subjects (total)\
4 subjects (SSC)Genotype-phenotypeOverexpression/increased dosage of MECP2 related with core features of ASD\[[@CR133]\]AGRE\
SSCData taken from \[[@CR327]\]8816 subjects (total)\
737 subjects (SSC)\
4449 (AGRE)Replication studyFindings could not be replicated from Skafidas paper\[[@CR328]\]SSC\
DNBSGenomic data38000 subjects (total)\
4358 subjects (SSC)\
19142 subjects (DNBS)General population studyGenetic influences on ASD risk found to influence typical variation in social and communication ability in the general population\[[@CR67]\]SSCBlood2256 subjectsDe novo and familial influencesFamilial influences were more significant in cases of high-functioning ASD conditions.\[[@CR327]\]SSCLymphoblasts1 subjectClinical reportDe novo microdeletion in chromosome 3q29 associated in person with ASD, childhood psychosis and intellectual disability\[[@CR68]\]SSCGenomic data1024 familiesDe novo mutation analysisSignificant role for loss of function mutations in ASD cases.\[[@CR329]\]AGRE\
SSCBlood8816 subjects (total)\
737 subjects (SSC)\
4449 subjects (AGRE)Predictive testingDiagnostic classifier containing 237 SNPs and 146 genes\[[@CR330]\]SSC\
AGREBlood975 subjects (total)\
392 subjects (SSC)\
585 subjects (AGRE)Genotype-phenotype studyNPAS1 found to repress generation of specific subtypes of cortical interneurons\[[@CR85]\]SSCBlood53 familiesWhole genome sequencingEnrichment of disruptive mutations in putative regulatory regions in ASD patients\[[@CR71]\]SSCBlood9231 subjectsGenotype-phenotype studyDisrupting mutations in *DYRK1A* were linked to a subset of 15 patients with a syndromic form of ASD/ID.\[[@CR331]\]SSCBlood903 familiesWESEnrichment of non-synonymous and potentially pathogenic mutations in mitochondrial DNA in ASD patients compared to controls. Transmission of potential pathogenic mutations differed between mother-ASD pairs and mother-sibling pairs\[[@CR332]\]SSCLymphoblasts1 familyMutation analysisPKA found to be an upstream regulator of *UBE3A*, where mutation in phosphorylation site results in hyperactivity of UBE3A\[[@CR333]\]SSCBlood686 subjects +\
612 families (SSC)WESBi-allelic mutations found in genes enriched in inherited ASD cases (*AMT*, *PEX7*, *SYNE1*, *VPS13B*, *PAH*, *POMGNT1*)\[[@CR333]\]SSCBlood928 subjectsWESStrong evidence that de novo mutations are associated with ASD\[[@CR69]\]SSCBlood, lymphoblasts and saliva1174 familiesCNV analysisSignificant associations found between ASD and *de novo* duplications of chromosome 7q11.23. *de novo* CNVs identified in 5 other regions, including 16p13.2\[[@CR334]\]SSCBlood and lymphoblasts2591 familiesCNV analysisDe novo CNVs associated with ASD. 6 loci and 65 genes identified, many targeting the chromatin or synapse\[[@CR335]\]SSCGenomic data2337 familiesTransmission disequilibriumExcess of truncating inherited mutations associated with ASD. *RIMS1, CUL7, LTZR1* identified as candidate genes\[[@CR336]\]SSCGenomic data411 familiesTransmission disequilibriumAffected ASD patients inherited more CNVs than their unaffected siblings, and these CNVs of ASD patients affected more genes. Enrichment of brain-specific genes in inherited CNVs amongst ASD patients\[[@CR312]\]SSCGenomic data10,942 subjects (total)\
4942 subjects (SSC)Biased transmission studyFrequent biased transmission of disruptive mutations to Low IQ ASD patients. Low and high IQ subjects can be distinguished by mutational load.Study numbers listed as families or subjects wherever applicable

The SSC has enabled detection of the ultra-rare "recurrent" CNVs. This included duplications of 7q11.23, 15q11.2 (*NIPA*) and 16p13.11, and deletion/duplication of 16p11.2, 16p13.2 (*USP7*), 1q21.1, 2p16.3, 7q31.1, 15q13.2--q13.3, 16p13.3, 20q13.33 and 22q11.21 \[[@CR60]\]. The SSC also helped identify recurrent gene mutations in ASD include *CHD8, NTNG1, GRIN2B, SCN1A* and *LAMC3*, which are important for transcriptional regulation, neuronal differentiation and function \[[@CR87]\].

*CHD8* was further evaluated as an ASD candidate gene in children with developmental delay or ASD, and 15 independent mutations were identified and enriched in a subset of ASD with altered brain size, distinct facial features and gastrointestinal complaints. Disruption of *CDH8* in zebra fish recapitulated some of the patient phenotypes including increased head size and impaired gastrointestinal motility \[[@CR88]\]. CHD8 is shown to control expression of other high-confidence de novo ASD risk genes such as *DYRK1A*, *GRIN2B* and *POGZ* \[[@CR89]\]. Mutation of *DYRK1A* was strongly linked to a subset of ASD patients with seizures at infancy, hypertonia, intellectual disability, microencephaly, dysmorphic facial features and impaired speech \[[@CR71], [@CR89]\]. *POGZ* gene which plays a role in cell cycle progression is also found to contribute to a subset of ASD with varying developmental delay, vision problems, motor coordination impairment, tendency of obesity, microcephaly, hyperactivity and feeding problems \[[@CR90]\].

Danish Newborn Screening (NBS) Biobank {#Sec9}
--------------------------------------

The NBS Biobank has a large collection of dried blood spot samples (DBSS), which are taken from new-borns 5--7 days after birth. They are sent to the New-born Screening lab at the Statens Serum Institute for analysis, and stored at −20 °C in a separate freezing facility at the NBS Biobank. Prior to collection, parents are informed via leaflets about the biobank, with focus on what the samples will be used for (documentation, testing and retesting, research, etc.). Participants can opt out of storage at any time via a letter to the department. For security, both the clinical data and biological samples are linked via a unique number, kept in separate buildings, and are accessible by authorised personnel only \[[@CR91]\]. The advantage of the NBS resources is that it provides a large amount of non-ASD controls as well as Danish ASD samples.

In the past 30 years the NBS Bio-collection has accumulated samples from 2.2 million individuals, around 65,000--70,000 samples per year from Denmark, Greenland and the Faroe Islands. Most recently this resource has been included under the Danish iPsych consortium with the Psychiatric Genomics Consortium (PGC), added 8--12 k samples to the PGC analysis and significantly increased its power to detect common genetic effects for ASD, which have been recently published \[[@CR92]\].

DBSS were also used to examine metabolites. A group led by Abdallah carried out a series of studies on Danish collections (Table [4](#Tab4){ref-type="table"}) to examine the potential role of cytokines and chemokines involved in signalling and immune response of ASD. Initially using amniotic fluid from the Danish Birth Cohort (DBC) collection \[[@CR93], [@CR94]\], they followed up with DBSS from new-borns crossed referenced from that cohort \[[@CR95], [@CR96]\]; they detected an imbalance of cytokines amongst ASD subjects compared to the controls. Most of the chemicals were lower than normal, such as Th-1 and Th-2 like cytokines involved in proliferation, priming and activation of these cell types, whereas a small number of cytokines displayed increased expression in ASD. The abnormal levels of these chemicals could lead to a hypoactive or "inactive" immune system in the brain, making it more susceptible to infection-related ASD. However, when chemokine levels were examined in amniotic fluid, no concrete relationship could be established.

The Autism Simplex Collection (TASC) {#Sec10}
------------------------------------

TASC is a trio-based international bio-collection that was assembled in collaboration with the Autism Genome Project and funded by Autism Speaks \[[@CR97]\]. Trios, comprised of both parents and a child affected with ASD with no known medical or genetic cause. Collection of samples took place between 2008 and 2010 across 13 sites; 9 in North America and 4 in Europe. Management, storage and distribution of TASC data are handled by the Centre for Collaborative Genetic Studies on Mental Disorders (CCGSMD) \[[@CR97]\]. Samples are housed at the NIMH and AGRE repositories both of which are located at Rutgers University.

So far, TASC has been used for GWAS studies \[[@CR66]\] and CNV studies \[[@CR72], [@CR98], [@CR99]\] and WES Studies \[[@CR16], [@CR100], [@CR101]\]. In addition, TASC has also been used in WGS as part of the MSSNG project, which is discussed below

Autism Inpatient Collection (AIC) {#Sec11}
---------------------------------

The AIC is a bio-collection for ASD research based on those on the serve end of the spectrum with severe language impairment, intellectual disability and self-injurious behaviour. This collection was founded on the basis that this segment of ASD patients are largely unrepresented in current studies. Bio-samples are initially recruited from 147 patients, and ongoing recruitment is estimated at 400 per year. Psychiatric, clinical and phenotypic data are collected in addition to blood samples for the creation of lymphoblastoid cell lines by RUCDR. Amongst this collection, over half are non-verbal, over 40% have intellectual disability and a quarter exhibit self-injurious behaviour \[[@CR24]\]. This collection has yet to be used in any genetics-based studies. The fact that many patients are on the severe end of the spectrum makes it a welcome addition, and it opens opportunities to explore this under-represented group.

Autism Tissue Program (ATP)/Autism BrainNet {#Sec12}
-------------------------------------------

The Autism Tissue Program, now the Autism Brain Network, is a post-mortem ASD brain collection coordinated by a network of parents, caregivers, physicians and pathologists. Brain samples are preserved in formalin and/or in −80 °C freezers to maximise the potential studies. In some cases, both hemispheres are fixed in formalin when there is freezing capacity or if the post-mortem interval exceeds 24 h. Corresponding clinical data include age, sex, ethnicity, diagnosis, brain size, cause of death, post-mortem interval and preservation method for the left and right hemisphere of the brain. Due to the rarity of the sample, a thorough application procedure assesses scope, scale and feasibility of proposed projects prior to access of tissue, with the expectation that data, images and presentations generated by research on the samples are provided back to the Autism Brain Network 3 months after formal release of publications \[[@CR102]\].

Brain pathology and molecular mechanisms have been the focus of studies using the ATP resource (Table [5](#Tab5){ref-type="table"}) although many studies looking at brain anatomy and cell morphology employed samples from this collection, molecular and genetic studies are the primary focus of this review. Such studies included transcriptomics \[[@CR103]--[@CR105]\], epigenetics \[[@CR29], [@CR106]--[@CR115]\] and alternative splicing \[[@CR116], [@CR117]\]. A key discovery was the identification of convergent molecular pathology linking to neuronal, glial and immune genes \[[@CR105]\] in a transcriptomics study that investigated the gene co-expression network between autistic and control brains. This led to the proposal of abnormal cortical patterning as an underlying mechanism due to attenuated differential expression in frontal and temporal cortices in ASD brains.

A recent study showed reduced Vitamin B12 in ASD brains \[[@CR118]\] where the ATP made a very large contribution. Post-mortem examination of brain tissue ranging from foetal to the elderly subjects also showed a marked decline of the brain vitamin B12 with age, together with lower activity of methionine synthase in the elderly, but the differences were more pronounced in ASD and schizophrenia subjects when compared to controls. Acetylation is an important post-translational modification in the field of epigenetics. ATP also made a significant contribution to a large-scale histone acetylome-wide association study (HAWAS) using the prefrontal cortex, cerebellum and temporal cortex in ASD patients and controls. Despite their heterogeneity, 68% of syndromic and idiopathic ASD cases shared a common acetylome signature at \>5000 cis-regulatory elements in the prefrontal cortex and temporal cortex. Aberrant acetylome was found to be associated with synaptic transmission, ion transport, epilepsy, behavioural abnormality, chemokinesis, histone deacetylation and immunity \[[@CR113]\].

The ATP sample was used in a methylation study that investigated differential methylation in CpG loci in three brain regions: temporal cortex, dorsolateral prefrontal cortex and cerebellum. Differential methylation of four genes (*PRRT1*, *C11orf21*/*TSPAN32*, *ZFP57* and *SDHAP3*) was detected. *PRRT1*, *C11orf21*/*TSPAN32* were hypomethylated while the latter two were hypermethylated \[[@CR109]\]. A further investigation in Brodmann's area also found a pattern of hypomethylation of a number of genes including *C11orf21/TSPAN32* that are implicated in immune function and synaptic pruning \[[@CR111]\]. These hypomethylated genes correlated with those showing overexpression by Voineagu.

The methylation studies have further uncovered dysregulation of *OXTR* and *SHANK3* genes in ASD. *OXTR* gene encoding oxytoxcin receptor was significantly hypermethylated in the peripheral blood cells and temporal cortex of ASD, highlighting a reduced oxytocin signalling in the aetiology of ASD \[[@CR108]\] and a therapeutic target of ASD. Differential methylation of the *SHANK3* gene was detected between ASD and control brains. They found that when three 5′ CpG islands of the gene were examined, they observed altered methylation also changed *SHANK3* splicing, with specific *SHANK3* isoforms expressed in ASD \[[@CR114]\].

This is echoed by a recent study, which reveals a dynamic microexon regulation associated with the remodelling of protein-interaction networks during neurogenesis. The neural microexons are frequently dysregulated in the brains of ASD, which is associated with reduced expression of *SRRM4* \[[@CR116]\]. The neuronal-specific splicing factor A2BP1/FOX1 and A2BP1-dependent splicing of alternative exons are also dysregulated in ASD brain \[[@CR105]\].

Replication studies and pooling resources {#Sec13}
-----------------------------------------

Research data from one bio-collection is not always replicable in another sample set. Therefore, cross-validation between different bio-collections will not only minimise false positive, but also identify the common risk factors and subset-specific factors. For example, a genome-wide survey was carried out to test trans-generational effects of mother-child interactions, and the AGRE and SSC samples were used to replicate the original findings of 16 ASD risk genes (*PCDH9*, *FOXP1*, *GABRB3*, *NRXN1*, *RELN*, *MACROD2*, *FHIT*, *RORA*, *CNTN4*, *CNTNAP2*, *FAM135B*, *LAMA1*, *NFIA*, *NLGN4X*, *RAPGEF4* and *SDK1*) involving urea transport and neural development. The results from the AGRE and SSC cohorts did not match the original study and showed fewer associations. When post-correction of the statistics was applied, the results lost their significance \[[@CR119]\]. This could partially be due to the differences in the array design with different coverage of SNPs and/or different methodologies.

The meta-analysis of five data sets including the AGRE and SSC demonstrates that females have a greater tolerance to CNV burden. This leads to a speculation that the maternal tolerance of the CNVs can result in decreased foetal loss amongst females compared to males, and that ASD-specific CNV burden contributes to high sibling occurrence. What is interesting about this study is that the results for high CNV burden in females are consistent throughout each data set. This is an example showing how multiple bio-collections can give a clearer picture in a combined study where individual studies may be ambiguous \[[@CR120], [@CR121]\].

Many major studies on the genetics of ASD have also been accomplished as a result of the collaborations amongst the institutions (Tables [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"}, [4](#Tab4){ref-type="table"}, [5](#Tab5){ref-type="table"} and [6](#Tab6){ref-type="table"}). An effort was made to evaluate the association of Fragile X Mental Retardation 2 locus (*AFF2*) with ASD using joint resources from AGRE (127 males) and SSC (75 males). *AFF2* encodes an RNA-binding protein, which is silenced in Fragile X. The study found that 2.5% of ASD males carry highly conserved missense mutations on *AFF2* gene which was significantly enriched in ASD patients, when compared to \>5000 unaffected controls \[[@CR122]\]. A WES was published recently, which sequenced the exomes of over 20,000 individuals, including those from the SSC and Swedish registries. The study identified 107 candidate genes, and reinforced ASD pathways of synaptic formation, chromatin remodelling and gene transcription. This study detected mutations in genes involved in calcium- (*CACNA2D3*, *CACNA1D*) and sodium-gated channels (*SCN2A*) which were related to neuronal function, and in genes involved in post-translational methylation (*SUV420H1*, *KMT2C*, *ASH1L*, *SETD5*, *WHSC1*) and demethylation (*KDM4B*, *KDM3A*, *KDM5B*, *KDM6B*) of lysine residues on histones which provided molecular basis linking to neuronal excitation and epigenetic changes in ASD \[[@CR86]\].Table 4Overview of studies using the DNSB collectionReferenceBio-collectionSamplesNumberStudyFindings\[[@CR136]\]DNSBDBSS1100 subjectsChemokine analysisAnalysis of crude estimates showed decreased levels of RANTES. Adjusted estimates showed no significance amongst 3 chemokines studied (RANTES, MCP-1, MIP-1A). Cautious suggestion of altered immunity in neonatal period amongst ASD patients\[[@CR96]\]DNSBDBSS1200 subjectsCytokine analysisSuggestive evidence of decreased levels of certain th-1 and th-2 like cytokines in newborns later diagnosed with ASD.\[[@CR136]\]DNSBDBSS1029 subjectsNeurotropic factor analysisDecreased level of neurotropic factors found in ASD patients during Neonatal periodStudy numbers listed as families or subjects wherever applicable Table 5Overview of studies using the ATP/Autism BrainNet collectionReferenceBio-collectionSamplesNumberStudyFindings\[[@CR337]\]ATP and AGREBrain tissue, blood and lymphoblasts18 subjects (ATP)\
841 families (AGRE)\
1029 families (total)Gene expression and association analysisAltered expression of mitochondrial genes in anterior cingulate gyrus, motor cortex and thalamus of ASD patients. Polymorphisms in *MTX2*, *NEFL* and *SLC25A27* found to be associated with ASD.\[[@CR338]\]ATPBrain tissue18 subjectsGene expression analysisReduced expression of several genes related to electron transport in anterior cingulate gyrus, motor cortex and thalamus of ASD patients\[[@CR339]\]ATPBrain tissue57 subjectsFunctional genomic studyAnalysis of CNVs showed differences of what pathways are altered between children and adults; cell number, cortical patterning and differentiation in the former, and signalling and repair pathways in the latter. Prefrontal cortex samples were used\[[@CR106]\]ATPBrain tissue33 subjectsGWASPatients with ASD had more genes that were up- or down-regulated in an- individual specific manner when prefrontal cortex tissue was examined\[[@CR340]\]ATPBrain tissue126 subjects (total)\
42 subjects (ATP)Sequencing studyRecurrent deleterious mutations found in *ARID1B*, *SCN1A*, *SCN2A* and *SETD2*. Higher proportion of mutations that are deleterious, protein-altering or cause loss-of-function in ASD patients compared to controls. Cortical and cerebellar tissue was used.\[[@CR107]\]ATPBrain tissue25 subjectsDeep sequencing studyAltered adenosine to inosine editing found in cerebella tissue from ASD patients. Dysfunctional for of editing enzyme *ADARB1* more frequently in ASD Cerebella\[[@CR341]\]ATPBrain tissue28 subjects (ATP)\
43 subjects (total)Gene expression analysisSignalling partners of *FMRP* and *GRM5* (*HOMER1, APP, RAC1, STEP*) shown to have altered expression in the cerebellar vermis and superior frontal cortex in ASD patients compared to controls.\[[@CR342]\]ATPBrain tissue19 subjectsmRNA analysisReduction of multiple GABA receptor subtypes (A6, B2, D, E, G2, T and P2) detected in cerebella vermis and superior frontal cortex ASD patients\[[@CR343]\]ATPBrain tissue25 subjectsAssay studyImbalance in isoforms of precursor BDNF protein found in fusiform gryrus of ASD patients\[[@CR103]\]ATPBrain tissue18 subjectsTranscriptional and epigenetic association analysisDownregulation of genes related to oxidative phosphorylation and protein translation. Associations were found between specific behaviour domains of ASD and gene expression modules related to myelination, immune response and purinergic signalling. Cerebral and Brodmann area 19 tissue was used\[[@CR108]\]ATPBrain tissue16 subjectsMethylation studyIncreased methylation was found for the gene *OTXR* in ASD patients in blood and DNA from the temporal cortex\[[@CR104]\]ATPBrain tissue107 subjectsTranscriptome analysisDysregulated gene expression associated with glial cells shown to have negative correlation with gene expression relating to synaptic transmission in ASD patients when Brodmann areas 10, 19 and 44 were analysed\[[@CR344]\]ATPBrain tissue32 subjectsTranscription analysisRORA may have dimorphic effects on gene expression in certain areas of cortical tissue between genders, and deficiency appears to cause greater gene dysregulation amongst males in both mice and humans\[[@CR345]\]ATPBrain tissue30 subjectsTranscription analysis*RPP25* expression is decreased in the prefrontal cortex of ASD patients\[[@CR116]\]ATPBrain tissue23 subjectsAlternate splicing analysis and discoveryA conserved group of microexons involved in modulation of interaction domains of proteins and neurogenesis is disrupted in patients with ASD\[[@CR29]\]ATPBrain tissue17 subjectsMethylation study*UBE3* implicated as a contributing gene to autism and Angelman syndrome\[[@CR346]\]ATPBrain tissue20 subjectsAnti-sense RNA studyDiscovery of anti-sense non-coding RNA that binds to moesin at 5p14.1 in ASD cerebral cortex tissue\[[@CR109]\]ATPBrain tissue40 subjectsMethylation study4 differentially methylated regions; 3 in temporal cortex and 1 in cerebellum. 3/4 regions were again found in different samples and brain regions.\[[@CR117]\]ATPBrain tissue and lymphoblasts36 subjects (total)Transcription and alternative splicing studyAccelerated decrease of MS gene transcription across ageing found in ASD patient cerebral cortex samples\[[@CR347]\]ATPBrain tissue73 subjectsMethylation studyCorrelation found between reduced expression of *MECP2* and increased methylation on the promoter region\[[@CR110]\]ATPBrain tissue24 subjectsMethylation studyHypomethylation of mir142 and upregulation of mi-RNAs targeting *OXTR* gene in prefrontal cortex of ASD brains\[[@CR348]\]ATPBrain tissue24 subjectsSignal transduction studyDownregulation of PI3K-Akt genes observed in fusiform gyrus tissue of ASD patients. Similar effects noted in rat brain tissue exposed to valproic acid\[[@CR349]\]ATPBrain tissue (ATP)\
neuronal cells6 subjectsCHiP study*RORA* found to regulate *2BP1*, *CYP19A1*, *HSD17B10*, *ITPR1*,\
*NLGN1* and *NTRK2* via transcription. Low levels of RORA causes dysregulation of these genes and associated pathways. Prefrontal cortex and cerebellum tissue was used.\[[@CR350]\]ATPBrain tissue (ATP)153 families (other)\
54 subjects (ATP)Functional characterisation studyVariant of the HTR2A gene rs6311 in ASD patients has lower level of expression and contains extended 5′untranslated region. Speculation that this variant could be a risk factor in ASD. Frontopolar cortex tissue was used.\[[@CR351]\]ATPBrain tissue28 subjectsMicro-RNA studyDifference in pattern of micro-RNA expression between ASD superior temporal gyrus samples and controls. Further evidence that *Mir-320*, *Mir-132* and *Mir-302* are involved in ASD.\[[@CR113]\]ATPBrain tissue94 subjects (total)\
51 subjects (ATP)Acetylome studyCommon acetylome signatures found amongst 68% of ASD cases in 5000 regulatory regions in the prefrontal and temporal cortex. Acetylome profiles were not affected by SNPs at these regulatory regions.\[[@CR352]\]ATP and AGREBrain tissue, blood and lymphoblasts21 subjects (ATP)\
252 families (AGRE)Association studyVariants of *LMX1B* show modest association with ASD. Analysis of mRNA from anterior cingulate gyrus is much lower in ASD patients compared to controls.\[[@CR105]\]ATPBrain tissue36 subjectsGene co-expression network analysisTranscriptional and splicing dysfunction implicated in disorder. Enrichment for genes in glial, immune and neuronal modules. Gene *A2BP1* linked to alterations in splicing. Studies based on using temporal cortex, frontal cortex and cerebellum\[[@CR353]\]ATPBrain tissue28 subjects (total)\
8 subjects (ATP)Gene expression analysisGenes expressed at higher levels in males enriched in upregulated genes in post-mortem neocortical tissue in ASD patients, including astrocyte and microglia markers\[[@CR118]\]ATPBrain tissue (ATP)\
and placenta12 subjects (ATP)\
64 subjects (total)Vitamin B12 studyReduced levels of B12 found in ASD, aged and Schizophrenic patients compared to controls. oxidative stress found in ASD and Schizophrenia patients. Frontal cortex tissue was used\[[@CR114]\]ATPBrain tissue98 subjectsMethylation studyAltered methylation patterns discovered in *SHANK3* gene in cerebella tissue of ASD patients\[[@CR115]\]ATPBrain tissue20 subjectsEpigenetic studyEnrichment of 5-hmc in cerebella tissue may be associated with increased binding by *MECP2* to *RELN* and *GAD1* promotorsStudy numbers listed as families or subjects wherever applicable Table 6Overview of studies using Multipe collectionsReferenceBiobankSample typeNumberStudyFindings\[[@CR119]\]SSC and AGREBlood and genomic data8044 subjects (AGRE)\
4348 subjects (SSC)Genome-wide survey on translational effectsInvestigation of maternal genetic effects in ASD. Validation using other data sets (SSC and AGRE) did not reproduce similar results).\[[@CR354]\]SSC and AGREGenomic and clinical dataSubjects (AGRE) 941\
1048 subjects (SSC)Gene association study*ATP2C2* and *MRPL19* found to be associated with language impairment and dyslexia, respectively\[[@CR122]\]SSC and AGREBloodAGRE--127 subjects\
SSC--75 subjectsParallel sequencing studyRare variants of the *AFF2* gene found to associated with ASD susceptibility in males\[[@CR355]\]SSC and AGREGenomic data359 subjects (AGRE)\
SS--885 subjectsGWASFemale protective effect in ASD is not mediated by a single genetic locus.\[[@CR356]\]AGRE and SSCGenomic data13 subjects (AGRE)\
3 subjects (SSC)WESLoss of *CTNND2* function linked to severe ASD\[[@CR86]\]SSC and TASCBlood and lymphoblasts15480 (total)\
2475(SSC)\
601(TASC)WES107 genes implicated in ASD. These genes are responsible for synaptic formation, chromatin remodelling and transcriptional regulation\[[@CR123]\]SSC and AGREBlood and lymphoblasts, genomic and clinical data5657 subjects (total)\
1555 subjects (AGRE)\
872 subjects (SSC)WESMutations in *SHANK1*, 2 and 3 accounts for 1 in 50 ASD cases. *SHANK1* mutations linked to mild effects, *SHANK2* for moderate and *SHANK2* for severe.Study numbers listed as families or subjects wherever applicable

Multiple bio-collections were employed to investigate *SHANK1, 2* and *3*, which are scaffolding proteins implicated in ASD. They devised a genetic screen and meta-analysis on patients and controls including cohorts from the AGRE, SSC and Swedish twin registry. In total, \~1% of all patients in the study had a mutation in this group of genes. The mutations in *SHANK3* had the highest frequency (0.69%) in patients with ASD and profound intellectual disability. *SHANK1* (0.04%) and *SHANK2* (0.17%) mutations occurred less frequently and were present in individuals with ASD and normal IQ, and ASD with moderate intellectual disability \[[@CR123]\].

Recently Autism, Speaks, in coordination with Google and Genome Canada, have launched another initiative; MSSNG (<https://www.mss.ng/>). The objective of the MSSNG project is whole genome sequencing of 10000 genomes of families affected by ASD. This incorporates AGRE along with other bio-collections to sequence the entire genomes of families with autistic children, and as of the summer of 2016, it has reached the halfway goal of 5000 genomes out of 10000, with the contribution of the AGRE (1746) and TASC (458). Two studies have been published from this initiative. In the first study, genomes from 200 families were sequenced \[[@CR124]\]. The findings revealed many of the de novo mutations (75%) from fathers, which increased dramatically with paternal age. Clustered de novo mutations however were mostly maternal origin, and located near CNV regions subject to high mutation. The ASD genomes were enriched with damaging de novo mutations, of which 15.6% were non-coding and 22.5% genic non-coding, respectively. Many of the mutations affected regulatory regions that are targeted by DNase 1 or involved in exon skipping \[[@CR124]\]. The second study \[[@CR125]\] featured 5205 sequenced genomes with clinical data, where an average of 73.8 de novo single nucleotide variants and 12.6 insertions/deletions/CNVs were detected per ASD patient. Eighteen new genes were also discovered (*CIC, CNOT3, DIP2C, MED13, PAX5, PHF3, SMARCC2, SRSF11, UBN2, DYNC1H1, AGAP2, ADCY3, CLASP1, MYO5A, TAF6, PCDH11X, KIAA2022* and *FAM47A*) that were not reported in ASD previously. These data clearly demonstrate that ASD is associated with multiple risk factors, and within an ASD individual, and multiple genetic alterations may be present. The Whole genome sequencing is therefore a powerful tool to detect genetic changes at all levels. Resources like MSSNG are valuable, and pooling of ASD bio-collections are essential for identification of the common and subgroup-specific pathways and drug targets of such a multi-factorial disease of ASD which involves hundreds of risk factors.

Stem cell research and autism spectrum stem cell resource {#Sec14}
---------------------------------------------------------

A major impediment to recent drug discovery particularly in the field of neuroscience is the lack of human cell models. The iPSC technology developed by Nobel Laureate Shinya Yamanaka has provided an excellent opportunity \[[@CR126]\]. Fibroblasts from patients' biopsy can be converted into iPSCs with defined transcription factors, which resemble embryonic stem cells and can become most cell types in our body. Therefore, patient-derived iPSCs may be used to investigate disease pathology, progression and mechanisms to create human disease models for drug screening and testing \[[@CR127], [@CR128]\].

The SSC has also commenced efforts to create iPSC lines from idiopathic ASD patients who have large head circumference but unknown gene association \[[@CR129]\]. The iPSCs were grown into organoids to mimic cortical development, and ASD organoids were shown to display a disproportionate ratio of inhibitory: excitatory neurons. The cortical gene *FOXG1* was overexpressed in ASD organoids, and this overexpression correlated with the severity of ASD and their head size \[[@CR129]\]. This study has demonstrated a proof-of-concept to model ASD in culture stem cells.

The Children's Hospital in Orange County California has set up a bio-collection dedicated to this task, the ASD Stem Cell Resource. ASD patients were screened and accepted based on the following criteria: ASD patients if they have no other conditions (i.e. trauma, stroke, seizure disorders) affecting the central nervous system other than ASD; if they have no features of other known genetic conditions (e.g. tuberous sclerosis); Fragile X patients if they are genotypically confirmed for the CGG repeat number of the *FMR1* mutation; idiopathic autism patients who are negative for *FMR1* mutation and chromosomal abnormality; if they possess an IQ of 40 or greater, and if they are 8-year-old or above. Skin punches and blood were collected in one location (MIND Institute), and fibroblasts were cultured and stored at the Hospital. The collection has been organised into seven groups; unaffected controls, Fragile X without ASD, Fragile X with ASD, permutations without ASD, permutations with ASD, ASD (not meeting full criteria for idiopathic status) and idiopathic ASD.

As of 2014, this resource was composed of iPSCs from 200 unaffected donors and patients. The collection includes fibroblasts, blood, iPSCs, iPSC-derived neuronal and glial cells. The first study published using this bio-collection was the iPSC models of Fragile X syndrome \[[@CR130]\]. The Fragile X patient fibroblasts were used to derive iPSCs and differentiate into neurons for transcriptomic analysis. The neuronal differentiation genes (*WNT1, BMP4, POU3F4, TFAP2C*, *PAX3*) were shown to be upregulated, whereas potassium channel genes (*KCNA1, KCNC3, KCNG2, KCNIP4, KCNJ3, KCNK9*, *KCNT1*) were downregulated in Fragile X iPSC-derived neurons. The temporal regulation of *SHANK1* and *NNAT* genes were also altered, with reduced *SHANK1* mRNA and increased *NNAT* mRNA in patient cells. While the stem cell collection is relatively new, it has great potential to facilitate brain cell culture in vitro, which would otherwise not be feasible by using post mortem brain tissue.

Discussion {#Sec15}
==========

It is clear from the studies reviewed here that large ASD bio-collections have had an undisputable impact on progressing genomic discovery in ASD, leading to enhanced understanding of ASD neurobiology. While many studies used private collections as sources for tissue and data, large and well characterised samples from the collections reviewed have supported the discovery of small genetic effects, e.g. in GWAS and rare genetic mutations such as pathogenic CNV and SNV but it is clear, as highlighted for other neurodevelopmental disorders such as Schizophrenia that larger samples are required. Both genetic and phenotypic heterogeneity are impediments to gene discovery. Large bio-collections aim to reduce these effects but challenges remain. Each of the bio-collections reviewed has its own strengths and limitations.

Phenotypic and genotypic heterogeneity {#Sec16}
--------------------------------------

Some of the bio-collections, e.g. SSC, AGRE, TASC, reduced phenotypic heterogeneity through the use of research gold standards for ASD diagnosis, ADI-R and ADOS. Different versions of these instruments based on the timeline when these data have been collected have been used. IQ measurement is more complex to calculate due to the broad range of IQ commonly included within bio-collections. Differences also exist in the clinical profile of subjects included in the different collections with some samples, e.g. SSC, comprised of more individuals with higher cognitive functioning relative to AGRE, TASC or AIC. Medical and psychiatric comorbidities \[[@CR7]\] have greater recognition but are not as systematically evaluated in each of the collections. Differences in ascertainment are also relevant. The SSC focused on simplex autism, i.e. families where only one child was affected to maximise the detection of rare variants. Consequently, the relative contribution of common genetic risk within the SSC sample appears reduced. In contrast to autism specific bio-collections, the DNSB, provides a large population-based sample with clinical diagnosis that can maximise power within GWAS studies to detect common genetic variation but does not provide in-depth clinical data for phenotype-genotype analyses. This was evident in the studies on amniotic fluid and DBSS where different diagnostic criteria would have been applied at the time of the subjects' diagnoses, meaning one criteria would have excluded subjects(ICD8) whereas another would not (ICD10) \[[@CR95], [@CR96]\] \[[@CR93], [@CR94]\].

Throughout the studies listed here, there is an imbalance of ethnicities of bio-collections, as many of the studies rely heavily on Caucasian/European descent, which has been pointed out in some journals \[[@CR131]\] and should consider diverse family structures \[[@CR132]\], which can otherwise lead to population stratification \[[@CR133]\]. Fortunately, efforts are underway to explore genetics of ASD in other countries such as China \[[@CR134]\] and Brazil \[[@CR135]\], which will reinforce many of the earlier findings covered in this review.

Samples {#Sec17}
-------

Large collections providing DNA for genomics studies have been advantageous; however, as studies move beyond the scope of genetics into transcriptomics, epigenomics and proteomics, a wider variety of sample types will be required. Serum will be valuable for investigating circulating metabolites and proteins that are expressed peripherally, including chemokines \[[@CR93], [@CR95]\], cytokines \[[@CR94], [@CR96]\], neurotropins \[[@CR136]\], MMPs \[[@CR137]\] and hormones \[[@CR138]\]; however, this may not be the most appropriate tissue to investigate brain relevant ASD genes and proteins. DBSS, which can be useful for WES \[[@CR139], [@CR140]\], methylation \[[@CR141]\] and gene expression \[[@CR142]\], would not be as useful as fresh drawn blood for WGS, as DBSS-derived DNA would need to be amplified prior to use for analysis, potentially causing bias.

However, human brain tissue is a rare resource; brain tissue is very difficult to access due to its scarcity, and the preservation methods used may limit studies being carried out. Also, the types of brain cells are dependent on brain tissue being used; neuronal tissue in grey matter or glial tissue in white matter. Many of the studies listed in the Autism BrainNet, for example, utilised certain sections of the brain; and the most commonly used sections are the prefrontal cortex, temporal cortex, Brodmann's area, cerebellum and cingulate gyrus. While findings from these sections have been of crucial importance, a capacity to model the entire brain and to observe progression of ASD development would be ideal, and patient's somatic cells can now be converted to iPSCs and then into disease cell types.

IPSCs have been used as disease models for Fragile X syndrome \[[@CR143]--[@CR145]\] and Rett syndrome \[[@CR146]\], and iPSCs have been generated from patents with deletions in *SHANK3* \[[@CR147]\] which are implicated in a number of neurodevelopmental disorders. The three-dimensional culture is developed and iPSCs can also be used to create mini-organoids, which can come very close to mimicking aspects of brain development \[[@CR129], [@CR148]\]. In addition to the brain cell types discussed earlier \[[@CR129], [@CR149]\], the iPSCs could be used to generate other cell types implicated in ASD co-morbidities, such as the gut \[[@CR88], [@CR150]\] and the blood brain barrier \[[@CR151], [@CR152]\].

Fibroblasts are the first cell type used to make iPSCs from mice \[[@CR126]\] and humans \[[@CR153]\] and remain as the most popular cell type for generating neural stem cells, neurons or iPSCs. Fibroblasts are easier to reprogram than many other somatic cells, and the reprogramming efficiency is between 0.1--1% depending on the reprogramming method \[[@CR154]\]. They require basic culture media and proliferate rapidly, so large numbers of fibroblasts can be generated in a short period. Unlike keratinocytes they require trained medical personnel to obtain skin biopsies, which could be distressing to some ASD patients. Low passages of fibroblasts are required for reprogramming as higher passages dramatically reduce reprogramming efficiency and increase genomic instability \[[@CR155]\].In addition to their use for IPSCs, fibroblasts can be used to investigate amino acid transport, and ASD fibroblasts were found to have greater affinity for transporting alanine, but less affinity for tyrosine---a key component for the synthesis of the neurotransmitter dopamine \[[@CR156]\]. Fibroblasts can be used as a proxy to investigate transport across the blood-brain barrier \[[@CR156], [@CR157]\] and to investigate calcium signalling \[[@CR158], [@CR159]\].

Keratinocytes can also be used for generating IPSCs \[[@CR160]\]. Collection is less invasive than skin biopsy and can be carried out by non-medical personnel. The hair samples are easy to transport and culture and transformed cells are easier to identify and isolate. Similar to fibroblasts, keratinocytes are reprogrammed at low passages and fewer methods have been employed to reprogram keratinocytes than fibroblasts. The lentiviral, retroviral and episomal reprogramming were tried successfully \[[@CR155], [@CR161], [@CR162]\], and keratinocytes were shown to have high reprogramming efficiency of 1--2%. The major challenge is the reproducibility of keratinocyte growth, and it often requires repeated rounds of hair plucking from a same donor.

Organization {#Sec18}
------------

There are many generic articles and white papers for biobanks available, including consensus best-practice recommendations. For those who may wish to start their own bio-collections, we have listed a few articles in Table [7](#Tab7){ref-type="table"} for further reading on topics pertaining to collection, management, sustainability and quality control. In addition, links to international guidelines can be found here (<http://www.oecd.org/sti/biotech/guidelinesforhumanbiobanksandgeneticresearchdatabaseshbgrds.htm>; <http://www.isber.org/?page=BPR>; <https://biospecimens.cancer.gov/practices/>). However, even when using best practice guidelines, the storage and use of bio samples will be subject to the laws where the facilities are located, and will vary from country to country \[[@CR163]\].Table 7Description of papers relating to aspects of biobankingReferenceSubject of paper\[[@CR357]\]Introduces concept of adding value to stakeholders (patient donors/funders/research customers) and to find balance between aspects of sustainability (acceptability/efficiency/accomplishment)\[[@CR358]\]Feasibility of simplified consent form for biobanking. Result indicates simplified forms combined with supplemental information for further reading effective in minimising form length and complexity\[[@CR359]\]Review paper detailing best practice guidelines for sample collection and storage, management of data and infrastructure. In addition, ethical, legal and social issues are explored\[[@CR360]\]Paper discussing aspects of embryonic stem cell banking that can be applied to iPSCS\[[@CR361]\]Key issues relating to delivery and safety testing of iPSC stocks for use in research and therapy. Importance of international and national coordinated banking systems are also discussed\[[@CR362]\]Description of enclosed culture system for iPSCS and neural precursors for use in preclinical and basic research

Participation and ethics {#Sec19}
------------------------

Stakeholders can have a considerable influence on how a bio-collection operates and how a bio-collection can be set up, managed and monitored \[[@CR164]\]. In addition to researchers, clinicians and parents in bio-collections of ASD research, autistic stakeholders should be included as part of the stakeholder group, which could help guide and inform how research is carried out. A recent survey \[[@CR165]\] was carried out amongst researcher-community engagement on ASD research in the UK. A high dissatisfaction and level of disengagement was expressed by parents and patients, who felt that research outcomes made little or no difference to their day-to-day lives and that they were not communicated, not involved or valued. Patients also felt that they did not receive follow-up and researchers were unapproachable and driven by data collection. Establishment and sustainability of a good stakeholder engagement are essential in ASD research and in biobanking. This will not only help guide research to subjects that matter to the community, but also the future of the biobank. One initiative, such as SPARK (Simons Foundation Powering Autism Research for Knowledge) is underway to encourage ASD communities in the USA to participate in ASD research. While such a goal is laudable, it is crucial that participants are engaged in the entire process. They are not just the suppliers of bio-collections for research and data collection, but also make an input into research areas, which directly impinge on the quality of their life. Meanwhile, regular public events to update research progress and challenges to the stakeholder community may help win their understanding, appreciation and continuous support.

The ethics and obtainment of consent are significant factors for bio-collection research. The main considerations include what information shall be given to potential donors regarding the protocol and its implications of the research, how consent should be obtained \[[@CR166]\] or what shall be done if consent was not clearly given \[[@CR167]\]. It is also a matter of debate whether the consent should be "broad" and if the patient shall consent to a framework of research; if ethical review of each project shall be carried out by independent committees, and what are the strategies to inform and renew consent if there is significant deviation of framework; where shall the consent be revisited and renewed for every new study \[[@CR168]\]; how the data will be protected and accessed \[[@CR169], [@CR170]\]; and how the findings will be communicated \[[@CR171]\]. The latter is especially important if findings are of clinical significance to certain donors or it may affect their health or well-being \[[@CR167]\]. These are the issues that each ethical application faces in making the application.

For people with ASD, it can be very complicated. Parents will give consent for their children if they want to donate samples for the bio-collection, but there is a question of adults who may not have the ability to give consent or to fully understand the implications. It is also important to clearly communicate what this research will mean for the patient and the family, including findings that may be of pathological as well as clinical significance. Liu and Scott have commented on how the discoveries made in ASD research can be distorted by media. If parents/patients are misled to believe that a cure will come out a few years down the road, this may lead to disappointment and make them reluctant to participate in further research. Liu and Scott pointed out that the Neurodiversity Movement group (high-functioning autists) would have issues with certain research. They will not participate in research if they feel it may threaten or undermine people with ASD \[[@CR128]\]. They prefer investment on services and therapies, rather than on genetic studies which may result in prevention of autistics being born \[[@CR172]--[@CR174]\], and the idea of curing autism is a complicated topic of debate \[[@CR175]\].

For iPSC research, it was suggested to educate participants on the current state of research, to clearly explain the benefits and risks of biopsy donation and to consult the ASD community on research focus of an ASD bio-collection and on distribution of the cell lines \[[@CR128]\]. For clinical trials of stem cells, stem cell counsellors shall inform participants the benefits and risks of enrolling in stem cell trials and to safeguard them from the dangers of stem cell tourism. Such an approach should also be considered for ASD-related studies \[[@CR176]\].

Conclusions {#Sec20}
===========

In conclusion, bio-collections have been shown as valuable resources and enabled large-scale studies on ASD. The recent genetic studies have begun to reveal de novo mutations on major cellular pathways \[[@CR17], [@CR177]\]. There is also emerging evidence that ASD continuum contains subgroups with discrete mutations in specific genes such as *CDH8* \[[@CR88]\], *DYRK1A* \[[@CR71]\] and POGZ \[[@CR90]\] and gene mutations like *NRXN1* \[[@CR28], [@CR60], [@CR73], [@CR178], [@CR179]\] and *SHANKs* \[[@CR72], [@CR98], [@CR114], [@CR123]\] recurring in broad populations. There is a vast amount of clinical and biological information available in these bio-collections, and the data are in the need for concrete guidelines on ethics and governance. The communication and trust shall be maintained between the researchers and families who have given biological and personal information. Finally, the availability of iPSC resources dedicated to idiopathic and syndromic forms of ASD could be a tremendous boon to the research community and such models are anticipated to be complementary with animal models and to speed up the development of therapeutic interventions for ASD. They could open up the possibilities of functional studies of ASD on a large scale and could become a future model for other iPSC bio-collections to be set up worldwide.

ADI-R

:   Autism Diagnostic Interview--Revised

ADOS

:   Autistic Diagnostic Observation Schedule

AGP

:   Autism Genome Project

AGRE

:   Autism Genetic Resource Exchange

AIC

:   Autism Inpatient Collection

ASD

:   Autism spectrum disorders

ATP

:   Autism tissue program

CAN

:   Cure Autism Now Foundation

CCGSMD

:   Centre for Collaborative Genetic Studies on Mental Disorders

CNV

:   Copy number variation

DBC

:   Danish Birth Cohort

DBSS

:   Dried blood spot samples

DNSB

:   Danish Newborn Screening Biobank

DSM-5

:   Diagnostic and Statistical Manual of Mental Disorders

GSH

:   Glutathione

GWAS

:   Genome-wide association study

HAWAS

:   Histone acetylome-wide association study

HBDI

:   Human Biological Data Interchange

ICD

:   International Statistical Classification of Diseases and Related Health Problems

iPSC

:   Induced pluripotent stem cells

MMP

:   Matrix metalloproteinase

MPLA

:   Multiplex ligation-dependent probe amplification

PDD-NOS

:   Pervasive developmental disorder not otherwise specified

RUCDR

:   Rutgers University Cell and DNA Repository

SCD

:   Social (pragmatic) communication disorder

SNP

:   Single nucleotide polymorphism

SNV

:   Single nucleotide variation

SSC

:   Simons Simplex Collection

TASC

:   Autism Simplex Collection

WES

:   Whole exome sequencing study
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